Hormonal
Restricting sleep duration to 4 hours per night for 6 days significantly decreases circulating leptin levels (mean -19%, maximal -26%) and reduces the amplitude of the diurnal leptin rhythm compared to extended sleep (12 hours).
If you consistently sleep less than 7-8 hours, your body produces less leptin, the hormone that signals fullness. This happens even if you don't change your diet. To manage appetite and prevent overeating, prioritize getting 8 hours of sleep as rigorously as you prioritize your food choices.
Mean levels, maximal levels, and rhythm amplitude of leptin were decreased (-19%, -26%, and -20%, respectively) during sleep restriction compared with sleep extension.
Why this rating
Randomized crossover design with controlled caloric intake and activity, though small sample size (n=11).
Source
Leptin Levels Are Dependent on Sleep Duration: Relationships with Sympathovagal Balance, Carbohydrate Regulation, Cortisol, and Thyrotropin
Karine Spiegel et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2004-1003
More from this paper
- Sleep restriction (4 hours/night) increases evening cortisol levels and delays the nocturnal nadir, while simultaneously decreasing TSH levels and amplitude, indicating a disruption of the hypothalamo-pituitary-adrenal and thyroid axes.Good
- Sleep restriction (4 hours/night) impairs glucose tolerance and increases post-breakfast insulin resistance, as measured by elevated HOMA values, despite similar insulin levels to rested conditions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →